Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei
- 3 October 2011
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 108 (41), 17165-17170
- https://doi.org/10.1073/pnas.1111020108
Abstract
Known mechanisms of resistance to β-lactam antibiotics include β-lactamase expression, altered drug target, decreased bacterial permeability, and increased drug efflux. Here, we describe a unique mechanism of β-lactam resistance in the biothreat organism Burkholderia pseudomallei (the cause of melioidosis), associated with treatment failure during prolonged ceftazidime therapy of natural infection. Detailed comparisons of the initial ceftazidime-susceptible infecting isolate and subsequent ceftazidime-resistant variants from six patients led us to identify a common, large-scale genomic loss involving a minimum of 49 genes in all six resistant strains. Mutational analysis of wild-type B. pseudomallei demonstrated that ceftazidime resistance was due to deletion of a gene encoding a penicillin-binding protein 3 (BPSS1219) present within the region of genomic loss. The clinical ceftazidime-resistant variants failed to grow using commonly used laboratory culture media, including commercial blood cultures, rendering the variants almost undetectable in the diagnostic laboratory. Melioidosis is notoriously difficult to cure and clinical treatment failure is common in patients treated with ceftazidime, the drug of first choice across most of Southeast Asia where the majority of cases are reported. The mechanism described here represents an explanation for ceftazidime treatment failure, and may be a frequent but undetected resistance event.Keywords
This publication has 31 references indexed in Scilit:
- Genomic acquisition of a capsular polysaccharide virulence cluster by non-pathogenic Burkholderia isolatesGenome Biology, 2010
- Molecular Basis of Rare Aminoglycoside Susceptibility and Pathogenesis of Burkholderia pseudomallei Clinical Isolates from ThailandPLoS Neglected Tropical Diseases, 2009
- Variations in Ceftazidime and Amoxicillin-Clavulanate Susceptibilities within a Clonal Infection of Burkholderia pseudomalleiJournal of Clinical Microbiology, 2009
- Clinically Relevant Chromosomally Encoded Multidrug Resistance Efflux Pumps in BacteriaClinical Microbiology Reviews, 2006
- Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infectionsNature Reviews Microbiology, 2006
- Extended-Spectrum β-Lactamases: a Clinical UpdateClinical Microbiology Reviews, 2005
- Modified Virulence of Antibiotic-Induced Burkholderia pseudomallei FilamentsAntimicrobial Agents and Chemotherapy, 2005
- Highly resistant Burkholderia pseudomallei small colony variants isolated in vitro and in experimental melioidosisMedical Microbiology and Immunology, 1999
- Mechanisms of Resistance to Cephalosporin AntibioticsDrugs, 1987
- Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureusJournal of Antimicrobial Chemotherapy, 1983